BioImage
From Wikipedia, the free encyclopedia
| BioImage | |
|---|---|
 |
|
| Type | Private |
| Founded | 1999 |
| Headquarters | Soeborg, Denmark |
| Key people | Patrik Dahlén (CEO) Steven Butcher, (CSO) Edwin Moses (Chairman of the Board) Axel Ullrich (Chairman of the Scientific Advisory Board) |
| Industry | Biotechnology |
| Products | licensing and services around the proprietary RedistributionTM drug discovery technology |
| Revenue | (not available) |
| Website | http://www.bioimage.com/ |
BioImage is a Danish biotechnology company that was demerged from Novo Nordisk in 1999.
BioImage specializes in developing and selling proprietary bioassays to biopharmaceutical companies and research institutions. It also develops bioassays on a contract service basis.
The company has made broad patents covering "any genetically encoded protein fusion to a luminophore, with subsequent monitoring of the protein's translocation within a cell as the primary readout for drug discovery assays." This intellectual property, trademarked Redistribution, allows many collaborations and out-licensing activities with biopharmaceutical companies.[1]
In April 2006, BioImage was acquired by Thermo Fisher Scientific. The merger was complete in November 2006.[2]
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
 |
This Danish corporation or company article is a stub. You can help Wikipedia by expanding it. |
